Loading
A phase 1/2 trial of Atezolizumab, Ifinatamab deruxtecan in small-cell lung cancer, run by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), active and no longer recruiting.
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) is a phase 1/2 interventional study registered as NCT04471727 by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), with 232 participants planned, started 2020-12-14 and due to reach its primary completion in 2028-01-28. Interventions recorded: Gocatamig, Atezolizumab, Ifinatamab Deruxtecan (I-DXd). Conditions listed: Small-Cell Lung Cancer, Neuroendocrine Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ifinatamab deruxtecan, Atezolizumab, Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Ifinatamab deruxtecan, Atezolizumab, Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Ifinatamab deruxtecan, Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Ifinatamab deruxtecan, Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Ifinatamab deruxtecan, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/